Breaking News

Emergent Pays $125M for Sanofi’s Small Pox Biz

Addition of ACAM2000, the only FDA-licensed smallpox vaccine, expands and diversifies portfolio of medical countermeasures

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Emergent BioSolutions has acquired the ACAM2000 business of Sanofi for $125 million. The upfront cost is $97.5 million with up to $27.5 million in near-term contingent regulatory and manufacturing-related milestones. ACAM2000 (Smallpox (Vaccinia) Vaccine, Live) is the only vaccine licensed by the U.S. FDA for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection. Emergent also takes control of an existing 10-year contract originally valu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters